MedTrace Logo

Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

NCT00319306 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2009-03-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether patients with asthma are better able to manage and control their symptoms by using one inhaler daily that both prevents as well as treats the symptoms of an asthma exacerbation.

Conditions

Interventions

DRUG

Budesonide/formoterol

DEVICE

Symbicort® Turbohaler®

Sponsors & Collaborators

Principal Investigators

  • Iain Small, MD · General Practitioner

  • AstraZeneca UK Medical Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319306 on ClinicalTrials.gov